The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration

被引:28
作者
Davis, JL
Papich, MG
Weingarten, A
机构
[1] N Carolina State Univ, Coll Vet Med, Clin Pharmacol Lab, Dept Mol & Biomed Sci, Raleigh, NC 27606 USA
[2] Schering Plough Corp, Anim Hlth, Union, NJ USA
关键词
D O I
10.1111/j.1365-2885.2006.00737.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to determine the pharmacokinetics and physicochemical characteristics of orbifloxacin in the horse. Six healthy adult horses were administered oral and intravenous orbifloxacin at a dose of 2.5 mg/kg. Plasma samples were collected and analyzed by high-pressure liquid chromatography with ultraviolet detection. Plasma protein binding and lipophilicity were determined in vitro. Following i.v. administration, orbifloxacin had a terminal half-life (t(1/2)) of 5.08 h and a volume of distribution (V-d(ss)) of 1.58 L/kg. Following oral administration, the average maximum plasma concentration (C-max) was 1.25 mu g/mL with a t(1/2) of 3.42 h. Systemic bioavailability was 68.35%. Plasma protein binding was 20.64%. The octanol:water partition coefficient (pH 7.4) was 0.2 +/- 0.11. No adverse reactions were noted during this study. Dosage regimens were determined from the pharmacokinetic-pharmacodynamic parameters established for fluoroquinolone antibiotics. For susceptible bacteria, an oral dose of approximately 5 mg/kg once daily will produce plasma concentrations within the suggested range. This dose is suggested for further studies on the clinical efficacy of orbifloxacin for treatment of susceptible bacterial infections in the horse.
引用
收藏
页码:191 / 197
页数:7
相关论文
共 33 条
  • [11] PHARMACOKINETICS OF CIPROFLOXACIN IN PONIES
    DOWLING, PM
    WILSON, RC
    TYLER, JW
    DURAN, SH
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1995, 18 (01) : 7 - 12
  • [12] PHARMACODYNAMICS OF A FLUOROQUINOLONE ANTIMICROBIAL AGENT IN A NEUTROPENIC RAT MODEL OF PSEUDOMONAS SEPSIS
    DRUSANO, GL
    JOHNSON, DE
    ROSEN, M
    STANDIFORD, HC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) : 483 - 490
  • [13] Epstein K, 2004, VET THER, V5, P155
  • [14] Moxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing
    Gardner, SY
    Davis, JL
    Jones, SL
    Lafevers, DH
    Hoskins, MS
    Mcarver, M
    Papich, MG
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2004, 27 (01) : 57 - 60
  • [15] GIBALDI M, 1982, PHARMACOKINETICS, P1
  • [16] Giguere S, 1996, AM J VET RES, V57, P1025
  • [17] Haines GR, 2001, CAN J VET RES, V65, P181
  • [18] Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones
    Hannan, PCT
    Windsor, GD
    deJong, A
    Schmeer, N
    Stegemann, M
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) : 2037 - 2040
  • [19] THE IMPORTANCE OF PHARMACOKINETIC-PHARMACODYNAMIC SURROGATE MARKERS TO OUTCOME - FOCUS ON ANTIBACTERIAL AGENTS
    HYATT, JM
    MCKINNON, PS
    ZIMMER, GS
    SCHENTAG, JJ
    [J]. CLINICAL PHARMACOKINETICS, 1995, 28 (02) : 143 - 160
  • [20] Pharmacokinetics of enrofloxacin in horses after single intravenous and intramuscular administration
    Kaartinen, L
    Panu, S
    Pyorala, S
    [J]. EQUINE VETERINARY JOURNAL, 1997, 29 (05) : 378 - 381